Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis
J Dermatol. 2024;51:1559–1571 doi: 10.1111/1346-8138.17448
Tsai et al. conducted a systematic literature review and network meta-analysis evaluating deucravacitinib and other systemic treatments for moderate-to-severe plaque psoriasis in Asian populations. The authors reported that deucravacitinib achieved PASI75 and PASI90 response rates of 66% and 40%, respectively, higher than placebo and apremilast.